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Abstract
Objective To evaluate the effectiveness of integrated care for chronic
physical diseases and depression in reducing disability and improving
quality of life.
Design A randomised controlled trial of multi-condition collaborative
care for depression and poorly controlled diabetes and/or risk factors
for coronary heart disease compared with usual care among middle
aged and elderly people
Setting Fourteen primary care clinics in Seattle, Washington.
Participants Patients with diabetes or coronary heart disease, or both,
and blood pressure above 140/90 mm Hg, low density lipoprotein
concentration >3.37 mmol/L, or glycated haemoglobin 8.5% or higher,
and PHQ-9 depression scores of ≥10.
Intervention A 12 month intervention to improve depression, glycaemic
control, blood pressure, and lipid control by integrating a “treat to target”
programme for diabetes and risk factors for coronary heart disease with
collaborative care for depression. The intervention combined self
management support, monitoring of disease control, and
pharmacotherapy to control depression, hyperglycaemia, hypertension,
and hyperlipidaemia.
Main outcome measures Social role disability (Sheehan disability
scale), global quality of life rating, and World Health Organization
disability assessment schedule (WHODAS-2) scales to measure
disabilities in activities of daily living (mobility, self care, household
maintenance).
Results Of 214 patients enrolled (106 intervention and 108 usual care),
disability and quality of life measures were obtained for 97 intervention
patients at six months (92%) and 92 at 12 months (87%), and for 96
usual care patients at six months (89%) and 92 at 12 months (85%).
Improvements from baseline on the Sheehan disability scale (−0.9, 95%
confidence interval −1.5 to −0.2; P=0.006) and global quality of life rating
(0.7, 0.2 to 1.2; P=0.005) were significantly greater at six and 12 months
in patients in the intervention group. There was a trend toward greater
improvement in disabilities in activities of daily living (−1.5, −3.3 to 0.4;
P=0.10).
Conclusions Integrated care that covers chronic physical disease and
comorbid depression can reduce social role disability and enhance global
quality of life.
Trial registration Clinical Trials NCT00468676.
Introduction
Depression is more common among people with chronic
physical conditions.
1 When both mental and physical disorders
are present, the risks of disability in carrying out activities in
familyandhouseholdlifeareincreased.
2-4Aspeoplelivelonger
in both developed and developing countries, the prevalence of
chronic physical disease accompanied by depression is likely
to grow in proportion.
5 For these reasons, improving health
outcomes of people with chronic physical disease, particularly
those with psychological illness as well, is a major challenge
for improving the health of ageing populations worldwide.
6-9
Delay of the harmful effects of growing older has been called
“successful aging,” “healthy aging,” and “compression of
morbidity.”
10-13 Health promotion and disease prevention
interventions are often cited as effective strategies to enhance
successfulageing.Forexample,healthydiet,vigorousphysical
activity, sustained mental activity, and effective medical care
are believed to promote successful ageing.
10-14 The potential of
effective medical care to promote successful ageing among
people with major chronic conditions, however, has received
less attention than health promotion and disease prevention
strategies.
Although it is well established that depression impedes
successful ageing,
15 16 the potential for treatment of depression
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Research
RESEARCHto enhance ageing among people with chronic physical disease
is often overlooked. Such treatment has been found to reduce
disability among patients with arthritis,
17 diabetes,
18 19 heart
disease,
20 21 and chronic pain.
22 Integration of treatment for
depression into the care of chronic physical disease could
provide a means to enhance ageing among chronically ill
people.
23 Improved control of risk factors for coronary heart
disease, including blood pressure, glycaemic control among
people with diabetes, and low density lipoprotein cholesterol
concentration,enhancessuccessfulageingbypreventingmajor
cardiovascular and cerebrovascular events.
24 The associated
benefits of improved control of risk factors for coronary heart
disease on functional status and quality of life, however, are
less clear. While antihypertensive drugs can have negative
effects on specific dimensions of quality of life (such as sexual
function),
25 large trials of management of hypertension have
found either no overall effects on quality of life or modest
gains.
26 The ACCORD trial of intensive glycaemic control
among people with diabetes, which was stopped early because
of increased mortality in the intensive management group, did
not find clinically meaningful effects of intensive control on
health related quality of life.
27 Thus, previous research suggests
thattreatmentfordepressionmighthavemorerobustshortterm
effects in improving functional outcomes among patients with
chronic disease, whereas efforts to improve control of risk
factors for coronary heart disease can have long term benefits
through preventing major cardiovascular and cerebrovascular
events.
We evaluated the effects on function and health related quality
oflifeofanintegratedcaremanagementinterventionforchronic
physical disease and depression.
28 The intervention managed
inadequate blood pressure, glycaemic, and lipid control among
patients with diabetes or heart disease, or both, along with
managingcomorbidmajordepression.Incontrastwithprevious
evaluationsofdepressiontreatmentamongpatientswithchronic
disease, integrated care simultaneously covered physical and
psychological aspects of illness in combination. We assessed
whether integrated care was associated with reduced disability
and improved quality of life, thereby contributing to successful
ageing among people with poorly controlled chronic physical
disease.Ininitialreportsfromthistrial,wefoundthatintegrated
care reduced depression and improved self monitoring and
managementofdrugs,
29resultinginimprovedglycaemic,blood
pressure,andlipidcontrol,
30therebyaffordingamorefavourable
profile for long term risks for major cardiovascular and
cerebrovascular events. We have now examined effects of
integratedcareondisabilityandqualityoflifeoutcomesamong
depressedpatientswithpoorlycontrolleddiabetesorriskfactors
for coronary heart disease, or both.
Methods
Participants were recruited from May 2007 to October 2009 in
14 Group Health primary care clinics.
Study participants
Study participants included adult men and women with a mean
age of 57.4 (SD 10.5) in the intervention group and 56.3 (SD
12.1) in the usual care group. We identified patients with
diabetes or coronary heart disease, or both, and blood pressure
above 140/90 mm Hg, low density lipoproteins above 3.37
mmol/L, or glycated haemoglobin (HbA1c) of 8.5% or higher.
Eligible patients were ambulatory, spoke English, and planned
to continue Group Health enrolment for 12 months. Exclusion
criteriawereterminalillness,residenceinlongtermcare,severe
hearing loss, planned bariatric surgery, pregnant or nursing,
ongoingpsychiatriccare,bipolardisorderorschizophrenia,use
ofantipsychoticdrugsormoodstabilisers,andmentalconfusion
suggestingdementia.Eligiblepatientsreceivedthepatienthealth
questionnaire-2
31 depression screen by post or telephone and,
if the results were positive, the patient health questionnaire-9
by telephone interview at a subsequent assessment. A score of
3orhigheronthepatienthealthquestionnaire-2and10orhigher
onthepatienthealthquestionnaire-9wasrequiredforeligibility.
Eligiblepatientscompletedabaselineinterviewandgaveverbal
consent for laboratory tests before an in-person visit, at which
they provided written informed consent before randomisation.
Randomisation and treatment assignment
Patientswereassignedtotreatmentgroupwithapermutedblock
designwithrandomlyselectedblocksizesoffour,six,andeight
patients. After baseline evaluation, a study nurse contacted
patients assigned to the intervention to initiate treatment. After
randomisation, patients in the usual care group were advised to
consult with their primary care physician to receive care for
depression,diabetes,orcoronaryheartdisease.Withpermission
from the patient, primary care physicians of those in the usual
caregroupwerenotifiedaboutdepressionandmeasuresofpoor
disease control. Primary care physicians also received results
of the six and 12 month laboratory tests.
Intervention
A 12 month intervention, called TEAMcare, sought to improve
depression and glycaemic, blood pressure, and lipid control by
integrating a treat to target
32 programme for diabetes and
coronaryheartdiseasewithcollaborativecarefordepression.
28 29
Theinterventioncombinedselfmanagementsupport,monitoring
ofindicatorsofdiseasecontrol,anddrugstocontroldepression,
hyperglycaemia, hypertension, and hyperlipidaemia. Patients
worked collaboratively with intervention nurses and primary
care physicians to create individualised clinical and self
management goals. In structured visits in the patient’s primary
carecliniceveryonetothreeweeks,nursesmonitoredpatients’
progress in depression (patient health questionnaire-9), control
ofmedicaldiseases,andselfcareactivities.Treatmentprotocols,
with commonly used drugs, guided adjustments in treatment
for patients not achieving specific goals.
Nurses followed patients proactively to support adherence to
drugs, using motivational coaching methods.
29 33 Patients
received self care materials including: The Depression
Helpbook,
34 a depression care DVD, a chronic disease
management booklet and other materials, and self monitoring
devices (blood pressure or blood glucose meters) appropriate
to their condition. Nurses received weekly supervision with a
psychiatrist (WK or PC), a primary care physician (EHBL or
BY),andapsychologist(EJL)toreviewnewcasesandprogress
of patients. An electronic registry supported tracking patient
health questionnaire-9 scores and concentrations of glycated
haemoglobin and low density lipoprotein and blood pressure.
The multidisciplinary consultants recommended initial choices
andchangesindrugstailoredtothepatient’shistoryandclinical
response.Thenursecommunicatedrecommendationsinchanges
in treatment to the primary care physician responsible for
managingdrugtreatment.Oncepatientsachievedtargetedlevels
for relevant measures, the nurse and patient developed a
maintenance plan. The nurses then followed up patients with
telephone calls every four to six weeks to complete a patient
healthquestionnaire-9andreviewadherenceandlaboratorytest
results. Patients whose disease control worsened were offered
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RESEARCHfollow-up and protocol based regimens for intensification of
treatment.
Disability and quality of life
Disability in carrying out life activities was assessed with the
Sheehandisabilityscale.
35Participantsratedtheextenttowhich
healthinterferedwithwork,familylife,andsociallifeonscales
of 0 to 10, where 0 was not at all and 10 was unable to carry on
any activities. The World Health Organization disability
assessment schedule (WHODAS-2)
36 was used to assess
disabilities in activities of daily living, including subscales for
mobility, self care, and household maintenance. Each item was
rated none (0), mild (1), moderate (2), severe (3), or
extreme/can’t do (4). The schedule was scored by summing the
15 items (range 0-60). We also administered an item assessing
days of reduced household work because of health. This item
has been used to monitor disability levels in populations, but it
is highly skewed limiting sensitivity to change.
37 Participants
rated global quality of life, including physical and mental
wellbeing, on a 0 to 10 scale, where 0 was “bad as you can
imagine” and 10 was “perfect.” A single item quality of life
rating has been found to correlate highly with longer scales but
might be less precise than multi-item scales.
38
Disease control
At baseline and six and 12 months, telephone interviewers
assessedsymptomsofdepression,disability,qualityoflife,and
otherstudymeasures.DepressionwasassessedbytheSCL-20.
39
Blood pressure and glycated haemoglobin were measured in
personatbaselineandsixand12monthsandfastinglowdensity
lipoprotein concentration at baseline and 12 months.
Study oversight
A data safety monitoring board initially reviewed methods and
reviewed outcomes every six months thereafter.
Statistical analyses
We describe disability and quality of life outcomes at six and
12 months after randomisation using linear regression models
adjusted for baseline values. Models that combine information
across time points were estimated with general estimating
equations to account for correlation. All analyses were based
on the treatment group to which the participant was randomly
assigned (intent to treat).
Results
Of 214 patients enrolled (106 intervention and 108 usual care),
88% completed all six month telephone and laboratory
assessments and 83% completed all 12 month assessments.
Patients in both groups were similar at baseline.
24 We obtained
measures on disability and quality of life for 97 patients at six
months (92%) and 92 at 12 months (87%) in the intervention
group and 96 at six months (89%) and 92 at 12 months (85%)
in the usual care group. The CONSORT diagram for this trial
is available elsewhere.
30
As previously reported, patients in the intervention group
showedsignificantlygreateroverallimprovementthancontrols
across glycated haemoglobin concentration, low density
lipoprotein concentration, systolic blood pressure, and SCL-20
depression outcomes.
30 The unadjusted differences in change
from baseline to 12 month follow-up between the intervention
and control groups were 0.58% for glycated haemoglobin, 0.18
mmol/L for low density lipoprotein, 5.1 mm Hg for systolic
blood pressure, and 0.40 for SCL-20 depression score (effect
size 0.67). These differences are comparable with effects
observedincollaborativecaretrialstargetingsingleconditions.
Improvement from baseline on the Sheehan disability scale
(P=0.006) and global quality of life rating (P=0.005) were
significantly greater at six and 12 months in patients in the
intervention group than among patients in the usual care group
(table⇓).Afteradjustmentforbaselinedifferences,at12months
theeffectsizewas0.30fortheSheehandisabilityscaleand0.39
for intervention effect on the global quality of life rating. The
WHODAS-2 measure of disabilities in activities of daily living
showed a modest non-significant trend towards greater
improvement in the intervention group than in the usual care
control group (P=0.10). The effect size for intervention effect
fordisabilitiesinactivitiesofdailylivingwas0.12at12months.
There was no difference in restricted days of household
maintenance activities between the two groups: mean 8.9
(SD=10.2) at baseline, 6.4 (SD=8.7) at six months, and 6.4
(SD=9.2) at 12 months in the intervention group and 8.4
(SD=10.0),5.6(SD=8.7),and6.7(SD=9.3),respectively,inthe
usual care group. The estimated mean difference was 0.0 for
six and 12 months (−0.3 to 0.4; P=0.8).
We examined confidence intervals of the estimated mean
differences (figure⇓), which were of moderate size for the
Sheehan disability score and global quality of life rating. The
confidence intervals of the estimated mean difference for the
WHODAS-2 measure of disabilities in activities of daily living
were larger.
Discussion
Principal findings
Amongpeoplewithpoorlycontrolledchronicphysicaldisease,
ageing can be accompanied by loss of function, reduced self
efficacy, and increased risk of depressive illness. An integrated
intervention for depression and chronic disease control can
reduce social role disability and improve global quality of life
among patients with depression and poorly controlled diabetes
or coronary heart disease, or both. Disabilities in activities of
dailyliving(mobility,selfcare,householdmaintenance)showed
a possible trend towards improved functioning, but the effect
size was small. Restricted activity days for household
maintenancedidnotshowaninterventioneffect.Previoustrials
of disease management interventions to improve control of
hypertension or glycaemic control have not found consistent
substantial associated benefits for functional status or health
related quality of life.
25-27
Strengths and weaknesses
Evaluation of confidence intervals for the mean differences
between intervention and control groups showed moderate
precision for evaluation of social role disability and global
quality of life outcomes. The uncertain and small benefits for
disabilities in activities of daily living indicate that approaches
to strengthening intervention effects for such disabilities, such
as targeting of specific tasks among patients with considerable
disabilities, might be needed.
As this trial had a smaller sample size than recommended for
evaluation of disability outcomes,
40 cautious interpretation is
warranted.Potentialbenefitsofintegratedcareforphysicaland
psychologicalcomorbiditiesneedtobeevaluatedacrossmultiple
trials. Results for benefits on functional disability, however,
have been consistently observed across previous trials of
treatment for depression in patients with chronic disease.
17-22
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RESEARCHThese consistent results suggest that treating depression as part
of a multi-condition collaborative care intervention could yield
improved quality of life and reduced social role disability, as
well as enhanced disease control and reduced depression.
The TEAMcare intervention included elements that sought to
empower participants, including motivational enhancement,
activation, problem solving, and scheduling of pleasant events,
as well as improved drug treatment for depression. Depression
treatment might directly improve functional outcomes by
increasing energy, self confidence, and interest in life activities.
We could not determine which components of a multifaceted
intervention were effective in improving functional outcomes.
Implications
Given ageing populations with an increasing prevalence of
chronic disease, successful ageing in people with poorly
controlled chronic physical disease and comorbid depression is
ofgrowingimportance.
7 8Asapproachestoenhancingsuccessful
ageinghavetendedtoemphasisehealthpromotionandstrategies
for prevention of disease, the associated benefits of depression
treatment for successful ageing among people with comorbid
chronicphysicalandpsychologicalillnessesmighthavereceived
lessattentionthanwarranted.Controlofriskfactorsforcoronary
heart disease to prevent major cardiovascular and
cerebrovasculareventsisconsistentwiththetraditionalemphasis
on preventive and health promotion strategies for enhancing
successful ageing. Integrated care for chronic disease and
comorbidpsychologicalillness,however,mighthaveassociated
benefits for successful ageing by improving health related
quality of life and functional status in the short term. We
concludethatsuccessfulageingcouldbeenhancedbyintegrated
care of multiple chronic conditions that covers both physical
and psychological illness.
InacosteffectivenessevaluationoftheTEAMcareintervention
it was found that intervention patients had a mean of 114 more
dayswithoutdepressionoveratwoyearperiod,andaprojected
0.335 additional quality adjusted life years (QALYs) based on
the predicted effect of improved disease control on QALYs.
41
The total outpatient costs of intervention patients (including
intervention costs) over a two year period averaged at $594
(£377, €430) less than the outpatient healthcare costs of control
patients, but the confidence intervals for the cost per
depression-free day were wide (mean $5.94, 95% confidence
interval −$29.96 to $19.17). The 95% confidence interval for
the cost per QALY ranged from −$2878 to $2878. This cost
effectiveness analysis did not consider the effects of the
intervention on current measures of functional status or quality
of life.
Depressionisassociatedwithsocialisolation,decreasedenergy
andmotivation,poorselfesteem,andinterpersonaldifficulties.
By covering these psychosocial impairments, depression
treatment can reduce disability and improve quality of life
among people whose depression occurs within the context of a
chronic physical disease.
Future research
Largescaleevaluationofpracticalapproachestoimplementing
integrated care for multiple conditions is needed. Large scale
trials should assess benefits for social role disability and quality
oflifeoutcomes,aswellasimprovedcontrolofchronicphysical
and psychological conditions. If our results can be replicated
and extended on a larger scale, the TEAMcare intervention
could provide a means of enhancing successful ageing among
people with poorly controlled chronic physical disease and
comorbid psychological illness.
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Table 1| Functional outcome measures according to integrated care (intervention) or usual care at 6 and 12 months
P value for differences Usual care Integrated care
Outcome 6 and 12 months 12 months Mean (SD) No of patients Mean (SD) No of patients
Sheehan social role disability scale (0-10): higher rating indicates greater disability
— — 5.1 (2.6) 107 5.6 (2.4) 106 Baseline
0.006 — 4.2 (2.6) 96 3.7 (3.2) 97 6 months
0.015 4.5 (2.9) 92 3.8 (3.0) 92 12 months
Global quality of life rating (0-10): higher rating indicates greater quality of life
— 4.7 (1.8) 107 4.2 (1.9) 106 Baseline
0.005 — 5.2 (1.8) 96 5.8 (2.4) 97 6 months
0.010 5.2 (1.9) 92 6.0 (2.2) 92 12 months
WHODAS-2 activities of daily living (0-4): higher rating indicates greater disability
— — 13.8 (9.6) 108 15.8 (9.6) 105 Baseline
0.1 — 12.4 (9.8) 96 12.3 (10.7) 97 6 months
0.2 12.9 (11.2) 92 12.9 (10.0) 92 12 months
WHODAS=World Health Organization disability assessment schedule.
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Disability and quality of life outcomes. Mean differences <0 on Sheehan disability scale and WHODAS-2 indicate reduced
disability levels, while mean difference >0 on QOL measure indicates improved quality of life
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